{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:43:55Z","timestamp":1792122235592,"version":"4.4.0"},"reference-count":44,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Multiple Myeloma (MM) is a complex hematological malignancy characterized by the clonal proliferation of malignant plasma cells within bone marrow (BM) [...]<\/jats:p>","DOI":"10.3390\/jcm14020327","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T04:54:08Z","timestamp":1736312048000},"page":"327","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["From Biology to Clinical Practice: The Bone Marrow Microenvironment in Multiple Myeloma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-807X","authenticated-orcid":false,"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Theagenion Cancer Hospital, 54639 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nature02040","article-title":"Osteoblastic cells regulate the haematopoietic stem cell niche","volume":"425","author":"Calvi","year":"2003","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12307-011-0072-9","article-title":"Angiogenesis and multiple myeloma","volume":"4","author":"Giuliani","year":"2011","journal-title":"Cancer Microenviron."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bone.2015.02.021","article-title":"Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast","volume":"75","author":"Reagan","year":"2015","journal-title":"Bone"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V73.2.517.517","article-title":"Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6","volume":"73","author":"Klein","year":"1989","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/1097-0142(19920315)69:6<1373::AID-CNCR2820690612>3.0.CO;2-1","article-title":"Interleukin-6 dependence of advanced malignant plasma cell dyscrasias","volume":"69","author":"Zhang","year":"1992","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood.V73.7.1915.1915","article-title":"Response patterns of purified myeloma cells to hematopoietic growth factors","volume":"73","author":"Anderson","year":"1989","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","article-title":"A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Kyle","year":"2013","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","article-title":"P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1038\/bcj.2016.37","article-title":"Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: Reduction by post-bortezomib and lenalidomide treatment","volume":"6","author":"Terpos","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bila, J., Katodritou, E., Guenova, M., Basic-Kinda, S., Coriu, D., Dapcevic, M., Ibricevic-Balic, L., Ivanaj, A., Karanfilski, O., and Zver, S. (2021). Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173940"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","article-title":"Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity","volume":"48","author":"Smith","year":"2018","journal-title":"Immunity"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7121580","DOI":"10.1155\/2016\/7121580","article-title":"Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation","volume":"2016","author":"Vladimirovna","year":"2016","journal-title":"J. Immunol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.4049\/jimmunol.1400833","article-title":"Noncanonical NF-kappaB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer","volume":"193","author":"Yu","year":"2014","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.7150\/jca.30102","article-title":"High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hadjiaggelidou, C., and Katodritou, E. (2021). Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194588"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00277-019-03657-3","article-title":"Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: Correlations with treatment outcome","volume":"98","author":"Hadjiaggelidou","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3324\/haematol.2016.154062","article-title":"Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression","volume":"102","author":"Pang","year":"2017","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/bjc.2016.11","article-title":"High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma","volume":"114","author":"Wang","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Giannakoulas, N., Ntanasis-Stathopoulos, I., and Terpos, E. (2021). The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094462"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/onc.2008.385","article-title":"Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma","volume":"28","author":"Kikuchi","year":"2009","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","article-title":"Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"25","author":"Yan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lv, Y., Luo, X., Xie, Z., Qiu, J., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., and Zuo, J. (2024). Prospects and challenges of CAR-T cell therapy combined with ICIs. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1368732"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9636897241293964","DOI":"10.1177\/09636897241293964","article-title":"CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies","volume":"33","author":"Su","year":"2024","journal-title":"Cell Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Letouze","year":"2024","journal-title":"Blood Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood.2023019758","article-title":"Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis","volume":"142","author":"Poos","year":"2023","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41375-018-0242-6","article-title":"APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: Therapeutic implications","volume":"33","author":"Tai","year":"2019","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41586-021-04217-4","article-title":"Spatial genomics enables multi-modal study of clonal heterogeneity in tissues","volume":"601","author":"Zhao","year":"2022","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1038\/s41596-021-00556-8","article-title":"CODEX multiplexed tissue imaging with DNA-conjugated antibodies","volume":"16","author":"Black","year":"2021","journal-title":"Nat. Protoc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3892\/ijo.2013.2134","article-title":"Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells","volume":"43","author":"Kawano","year":"2013","journal-title":"Int. J. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/2\/327\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:24:33Z","timestamp":1759919073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/2\/327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["jcm14020327"],"URL":"https:\/\/doi.org\/10.3390\/jcm14020327","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}